{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-26-000032","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.600060+00:00","generated_at":"2026-05-15T11:44:52.153502+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elicio Therapeutics enters $100M ATM facility; terminates prior $40M JonesTrading ATM","bullets":["Company entered ATM sales agreement to sell up to $100M of common stock through B. Riley Securities, JonesTrading, and Ladenburg Thalmann.","Agents will receive 3% commission on gross proceeds from any shares sold under the program.","Company terminated prior $40M ATM agreement with JonesTrading from June 2024, effective immediately.","Sales will be made at-the-market on Nasdaq under existing S-3 registration statement.","Company not obligated to sell any shares; program provides capital raising flexibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-26-000032","json":"https://secwatch.observer/filing/0001601485-26-000032.json","markdown":"https://secwatch.observer/filing/0001601485-26-000032.md","text":"https://secwatch.observer/filing/0001601485-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000032/0001601485-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000032/angn-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:44:52.153502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a2345e970f18996af07c95fe9a385ff6eadc79e","claim":"Elicio Therapeutics, Inc. terminated Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC (effective 2026-03-16).","evidence_excerpt":"On March 16, 2026, the Company delivered written notice to Jones to terminate the Jones Sales Agreement and the offering of shares contemplated thereby, effective upon delivery, pursuant to Section 12(b) of the Jones Sales Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000032/0001601485-26-000032-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"JonesTrading Institutional Services LLC"},{"label":"Effective","value":"2026-03-16"}]},{"claim_id":"bb3ce1896ce51152d7255b0cc71b540c8e1003b6","claim":"Elicio Therapeutics, Inc. entered into Sales Agreement with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. valued at $100.0 million (effective 2026-03-16).","evidence_excerpt":"On March 16, 2026, Elicio Therapeutics, Inc. (the “ Company ”) entered into an At Market Issuance Sales Agreement (the “ Sales Agreement ”) with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. (the “ Agents ”) with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share (the “ Common Stock ”), having an aggregate offering price of up to $100.0 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000032/0001601485-26-000032-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc."},{"label":"Value","value":"$100.0 million"},{"label":"Effective","value":"2026-03-16"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}